Document 2845
 DOCN  M94A2845
 TI    First evaluation of 20 HIV positive patients on treatment of AZT/ddI at
       the L.J. Engelmajer Association.
 DT    9412
 AU    Puchot P; Puppo P; Engelmajer ML; European Institute for Documentation
       and Research on Drug Abuse,; Grenade, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):211 (abstract no. PB0275). Unique
       Identifier : AIDSLINE ICA10/94369730
 AB    BACKGROUND: Numerous interesting works published in Berlin demonstrating
       the benefit of treatments with Combined convergents associating the
       Nucleoside Analogues (AZT + DDI or AZT + DDC) taking into consideration
       the appearance of viral resistance induced by reverse transcriptase
       mutations. METHOD: Twenty patients during a period of 4 months: Four
       patients were switched directly from AZT only to the association of
       AZT/DDI, Sixteen patients were being treated with DDI as monotherapy for
       two months before receiving the associated treatment. RESULTS: The
       results were evaluated according to the following: 1) The evolution of
       values of Absolute CD4 count and percentage of Total Lymphocyte count
       (see Graphics) 2) The evolution of values of P24 antigen and P24
       antibodies (see Graphics). 3) The associated treatment was interrupted
       in 3 patients for the following causes: Acute pancreatitis of iatrogenic
       origin, Herpes Zoster, treated with Zovirax, A PCP (pneumocystis
       carinii), treated with Bactrim was followed by a CMV infection with a
       localization at the retina for which treatment with Foscavir was
       initiated and continues presently. CONCLUSIONS: The duration of
       follow-up of the 20 patients that are receiving the associated treatment
       is only 4 months. It is not yet sufficient time to be able to evaluate
       its efficacy and tolerance, but we can state that apparently the
       association of both medications is much more effective than a
       monotherapy.
 DE    AIDS-Related Opportunistic Infections/PREVENTION & CONTROL
       Didanosine/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC  USE
       Drug Synergism  Drug Therapy, Combination  Human  HIV Antibodies/BLOOD
       HIV Core Protein p24/BLOOD  HIV Infections/*DRUG THERAPY  Leukocyte
       Count  Pancreatitis/CHEMICALLY INDUCED  Treatment Outcome  T4
       Lymphocytes  Zalcitabine/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS/*THERAPEUTIC  USE  Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE
       EFFECTS/*THERAPEUTIC  USE  CLINICAL TRIAL  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).